<DOC>
	<DOCNO>NCT00900432</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change may occur immune system may help kill cancer cell . PURPOSE : This laboratory study look anticancer immune response peripheral blood patient colon cancer .</brief_summary>
	<brief_title>Immune Response Peripheral Blood Patients With Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Quantify T cell specific tumor peptide ( carcinoembryonic antigen MUC1 ) peripheral blood patient colon cancer . OUTLINE : This open-label study . Patients undergo blood collection time follow-up , surgery , thoracentesis , paracentesis , leukapheresis ( â‰¤ 5 time per year ) . Blood analyze tumor peptide ( carcinoembryonic antigen MUC1 ) , circulate cytokine , lymphocyte response ELISA , ELISPOT , intracellular flow . PROJECTED ACCRUAL : A total 140 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colon cancer PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
</DOC>